As reported, single-agent therapy with BH3 mimetics caused tumor cell resistance to treatment by up-regulation of non-targeted anti-apoptotic proteins and increased activation of PI3K/AKT/mTOR pathway, providing a rationale for a combinatorial therapy (35, 36). The gene discussed is MTOR; the disease is neoplasm.